Cargando…

Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell–mediated antitumor immunity

Cancer immunotherapy targeting the TIGIT/PVR pathway is currently facing challenges. KIR2DL5, a member of the human killer cell, immunoglobulin-like receptor (KIR) family, has recently been identified as another binding partner for PVR. The biology and therapeutic potential of the KIR2DL5/PVR pathwa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Xiaoxin, Peng, Mou, Xing, Peng, Wei, Yao, Galbo, Phillip M., Corrigan, Devin, Wang, Hao, Su, Yingzhen, Dong, Xiaoshen, Sun, Qizhe, Li, Yixian, Zhang, Xiaoyu, Edelmann, Winfried, Zheng, Deyou, Zang, Xingxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663162/
https://www.ncbi.nlm.nih.gov/pubmed/36377656
http://dx.doi.org/10.1172/JCI163620
_version_ 1784830811296497664
author Ren, Xiaoxin
Peng, Mou
Xing, Peng
Wei, Yao
Galbo, Phillip M.
Corrigan, Devin
Wang, Hao
Su, Yingzhen
Dong, Xiaoshen
Sun, Qizhe
Li, Yixian
Zhang, Xiaoyu
Edelmann, Winfried
Zheng, Deyou
Zang, Xingxing
author_facet Ren, Xiaoxin
Peng, Mou
Xing, Peng
Wei, Yao
Galbo, Phillip M.
Corrigan, Devin
Wang, Hao
Su, Yingzhen
Dong, Xiaoshen
Sun, Qizhe
Li, Yixian
Zhang, Xiaoyu
Edelmann, Winfried
Zheng, Deyou
Zang, Xingxing
author_sort Ren, Xiaoxin
collection PubMed
description Cancer immunotherapy targeting the TIGIT/PVR pathway is currently facing challenges. KIR2DL5, a member of the human killer cell, immunoglobulin-like receptor (KIR) family, has recently been identified as another binding partner for PVR. The biology and therapeutic potential of the KIR2DL5/PVR pathway are largely unknown. Here we report that KIR2DL5 was predominantly expressed on human NK cells with mature phenotype and cytolytic function and that it bound to PVR without competition with the other 3 known PVR receptors. The interaction between KIR2DL5 on NK cells and PVR on target cells induced inhibitory synapse formation, whereas new monoclonal antibodies blocking the KIR2DL5-PVR interaction robustly augmented the NK cytotoxicity against PVR(+) human tumors. Mechanistically, both intracellular ITIM and ITSM of KIR2DL5 underwent tyrosine phosphorylation after engagement, which was essential for KIR2DL5-mediated NK suppression by recruiting SHP-1 and/or SHP-2. Subsequently, ITIM/SHP-1/SHP-2 and ITSM/SHP-1 downregulated the downstream Vav1/ERK1/2/p90RSK/NF-κB signaling. KIR2DL5(+) immune cells infiltrated in various types of PVR(+) human cancers. Markedly, the KIR2DL5 blockade reduced tumor growth and improved overall survival across multiple NK cell–based humanized tumor models. Thus, our results revealed functional mechanisms of KIR2DL5-mediated NK cell immune evasion, demonstrated blockade of the KIR2DL5/PVR axis as a therapy for human cancers, and provided an underlying mechanism for the clinical failure of anti-TIGIT therapies.
format Online
Article
Text
id pubmed-9663162
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Clinical Investigation
record_format MEDLINE/PubMed
spelling pubmed-96631622022-11-17 Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell–mediated antitumor immunity Ren, Xiaoxin Peng, Mou Xing, Peng Wei, Yao Galbo, Phillip M. Corrigan, Devin Wang, Hao Su, Yingzhen Dong, Xiaoshen Sun, Qizhe Li, Yixian Zhang, Xiaoyu Edelmann, Winfried Zheng, Deyou Zang, Xingxing J Clin Invest Research Article Cancer immunotherapy targeting the TIGIT/PVR pathway is currently facing challenges. KIR2DL5, a member of the human killer cell, immunoglobulin-like receptor (KIR) family, has recently been identified as another binding partner for PVR. The biology and therapeutic potential of the KIR2DL5/PVR pathway are largely unknown. Here we report that KIR2DL5 was predominantly expressed on human NK cells with mature phenotype and cytolytic function and that it bound to PVR without competition with the other 3 known PVR receptors. The interaction between KIR2DL5 on NK cells and PVR on target cells induced inhibitory synapse formation, whereas new monoclonal antibodies blocking the KIR2DL5-PVR interaction robustly augmented the NK cytotoxicity against PVR(+) human tumors. Mechanistically, both intracellular ITIM and ITSM of KIR2DL5 underwent tyrosine phosphorylation after engagement, which was essential for KIR2DL5-mediated NK suppression by recruiting SHP-1 and/or SHP-2. Subsequently, ITIM/SHP-1/SHP-2 and ITSM/SHP-1 downregulated the downstream Vav1/ERK1/2/p90RSK/NF-κB signaling. KIR2DL5(+) immune cells infiltrated in various types of PVR(+) human cancers. Markedly, the KIR2DL5 blockade reduced tumor growth and improved overall survival across multiple NK cell–based humanized tumor models. Thus, our results revealed functional mechanisms of KIR2DL5-mediated NK cell immune evasion, demonstrated blockade of the KIR2DL5/PVR axis as a therapy for human cancers, and provided an underlying mechanism for the clinical failure of anti-TIGIT therapies. American Society for Clinical Investigation 2022-11-15 /pmc/articles/PMC9663162/ /pubmed/36377656 http://dx.doi.org/10.1172/JCI163620 Text en © 2022 Ren et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Ren, Xiaoxin
Peng, Mou
Xing, Peng
Wei, Yao
Galbo, Phillip M.
Corrigan, Devin
Wang, Hao
Su, Yingzhen
Dong, Xiaoshen
Sun, Qizhe
Li, Yixian
Zhang, Xiaoyu
Edelmann, Winfried
Zheng, Deyou
Zang, Xingxing
Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell–mediated antitumor immunity
title Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell–mediated antitumor immunity
title_full Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell–mediated antitumor immunity
title_fullStr Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell–mediated antitumor immunity
title_full_unstemmed Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell–mediated antitumor immunity
title_short Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell–mediated antitumor immunity
title_sort blockade of the immunosuppressive kir2dl5/pvr pathway elicits potent human nk cell–mediated antitumor immunity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663162/
https://www.ncbi.nlm.nih.gov/pubmed/36377656
http://dx.doi.org/10.1172/JCI163620
work_keys_str_mv AT renxiaoxin blockadeoftheimmunosuppressivekir2dl5pvrpathwayelicitspotenthumannkcellmediatedantitumorimmunity
AT pengmou blockadeoftheimmunosuppressivekir2dl5pvrpathwayelicitspotenthumannkcellmediatedantitumorimmunity
AT xingpeng blockadeoftheimmunosuppressivekir2dl5pvrpathwayelicitspotenthumannkcellmediatedantitumorimmunity
AT weiyao blockadeoftheimmunosuppressivekir2dl5pvrpathwayelicitspotenthumannkcellmediatedantitumorimmunity
AT galbophillipm blockadeoftheimmunosuppressivekir2dl5pvrpathwayelicitspotenthumannkcellmediatedantitumorimmunity
AT corrigandevin blockadeoftheimmunosuppressivekir2dl5pvrpathwayelicitspotenthumannkcellmediatedantitumorimmunity
AT wanghao blockadeoftheimmunosuppressivekir2dl5pvrpathwayelicitspotenthumannkcellmediatedantitumorimmunity
AT suyingzhen blockadeoftheimmunosuppressivekir2dl5pvrpathwayelicitspotenthumannkcellmediatedantitumorimmunity
AT dongxiaoshen blockadeoftheimmunosuppressivekir2dl5pvrpathwayelicitspotenthumannkcellmediatedantitumorimmunity
AT sunqizhe blockadeoftheimmunosuppressivekir2dl5pvrpathwayelicitspotenthumannkcellmediatedantitumorimmunity
AT liyixian blockadeoftheimmunosuppressivekir2dl5pvrpathwayelicitspotenthumannkcellmediatedantitumorimmunity
AT zhangxiaoyu blockadeoftheimmunosuppressivekir2dl5pvrpathwayelicitspotenthumannkcellmediatedantitumorimmunity
AT edelmannwinfried blockadeoftheimmunosuppressivekir2dl5pvrpathwayelicitspotenthumannkcellmediatedantitumorimmunity
AT zhengdeyou blockadeoftheimmunosuppressivekir2dl5pvrpathwayelicitspotenthumannkcellmediatedantitumorimmunity
AT zangxingxing blockadeoftheimmunosuppressivekir2dl5pvrpathwayelicitspotenthumannkcellmediatedantitumorimmunity